Small Cap Gainers: PTGX, GOTU, OCUL
3:48 pm Monday, October 11th, 2021
Protagonist Therapeutics Inc (NASDAQ:PTGX) announced that the FDA has removed the full clinical hold on co’s clinical development program for rusfertide, which had been announced in mid-September; dosing in all clinical studies may be resumed. Co is preparing to initiate the Phase 3 registrational study for polycythemia vera in Q1 of 2022. Upgraded to Outperform at Northland Capital.
Gaotu Techedu Inc (NYSE:GOTU) breaks out to its highest levels since July on elevated volume as Chinese tutoring providers generally post gains. Various tech-exposed Chinese stocks see strength after a fine placed on Meituan was viewed as removing an “overhang”. (Related: TAL, EDU…)
Ocular Therapeutix Inc (NASDAQ:OCUL) received FDA approval for its supplemental NDA for DEXTENZA 0.4 mg for intracanalicular use for the treatment of ocular itching associated with allergic conjunctivitis. Co notes that this approval represents the first primarily office-based indication for DEXTENZA. Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery
